LGALS3 and idiopathic pulmonary fibrosis: GB0139 (formerly TD139), a novel, inhaled, small molecule Gal-3 inhibitor developed by Galecto Biotech, reduces fibrosis severity following bleomycin administration (MacKinnon et al., 2012; Delaine et al., 2016), and targets lung macrophages in IPF (Hirani et al., 2021).